Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Royalty Pharma logo

Royalty Pharma Cash Flow Statement

Operating, investing, and financing cash movements

Royalty Pharma generated $2.6B in operating cash flow over the trailing twelve months. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$2.6BNet Cash From Investing (TTM)-$2.6BNet Cash From Financing (TTM)-$646.8MNet Change In Cash (TTM)-$501.3M
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$24.5B
P/E Ratio29.63
ROE8.39%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Distributions from equity method investments—$13.4M———$3.7M
Net cash from operating activities$742.5M$596.1M$364M$702.6M$827.1M$718.2M
Distributions of earnings from equity method investees—$13.4M———$3.7M
Payments For Development Stage Funding$500K$50.5M——$50.5M$25.5M
Payments for Employee Equity Performance Awards$0$0$173K$1.7M$9.1M$9.7M
Payments For Operating Costs And Professional Services$72.4M$101.7M$94M$34.2M$58.2M$36.3M
Other royalty cash collections$29.5M$31.8M$24.1M$29.1M$29.1M$33.6M
Cash collections from financial royalty assets$777.5M$829.7M$726.5M$882.4M$916.1M$915.6M
Cash collections from intangible royalty assets$227K$177K$240K$264K$39K$3.8M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Distributions to noncontrolling interests$31.4M$53.8M$38.6M$34.3M$40.8M$39.9M
Cash acquired in connection with purchase of non-controlling interest$0$0$0$0$0—
Payment Of Dividends To Shareholders$93.7M$95.4M$93.2M$95.3M$94.3M$104.5M
Payments to Noncontrolling Interests$31.4M$53.8M$38.6M$34.3M$40.8M$39.9M
Payments To Noncontrolling Interests, Portfolio Receipts$81.2M$84.6M$89.2M$101.9M$79.1M$78M
Contributions from non-controlling interests - other$1M$1.1M$4.6M$15K$0$0
Contributions from legacy non-controlling interests - R&D$220K$220K$219K——$0
Other, net-$1K$0$0$0-$1.8M-$226K
Net cash from financing activities—-$941.3M-$507.8M—-$299.6M-$272.7M
Other financing activities-$1K$0$0$0-$1.8M-$226K
Repurchases of common stock$52.6M$708.8M$291.6M$146.5M$80.5M$50.1M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$805K$138.8M$796K$130M$6.7M$173.5M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Payments For Milestones$25M$50M$218.6M$0$2.7M$50M
Payments To Acquire Equity Securities, FN-NI$0$4.4M——$54M$22.5M
Proceeds from equity securities$24.6M$0$0$0$34.7M$375K
Proceeds from sales of available for sale debt securities$0$510.6M———$0
Sale of investments$12.6M$12.6M$2.9M$2.9M$2.9M$4.3M
Net cash from investing activities-$505.6M$503.9M-$312M-$958.3M-$847.8M-$477.9M
Net change in loans and leases$496.4M$1.1M$1.1M$961.9M$733.7M$452.4M
Proceeds from maturities/sales of investments$12.6M$12.6M$2.9M$2.9M$2.9M$4.3M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net increase (decrease) in cash—$158.7M-$455.8M$307M-$320.2M-$32.3M
Proceeds From Interest Received$9M$12M$8.7M$7.2M$6.4M$6.5M